Prophylactic and Therapeutic Efficacy of Poly(I,C)-LC against Rift Valley Fever Virus Infection in Mice,
ARMY MEDICAL RESEARCH INST OF INFECTIOUS DISEASES FORT DETRICK MD
Pagination or Media Count:
The prophylactic and therapeutic efficacy pf polyriboinosinic- polyribocytidylic acid stabilized with poly-L-lysine and carboxymethylcellulose polyI,C-LC was evaluated in female Swiss Webster mice against a lethal infection of Rift Valley fever virus RVFV. Prophylactically, the best effect was obtained with 2-3 doses of 1-20 micrograms pollyI,C-LC, which fully protected the mice in a schedule-dependent fashion against an LD100 RVFV challenge. Multiple intermittent therapeutic administration of 20 micrograms polyI,C-LC 24 or 48 h after infection protected 100 and 50 or the mice, respectively. When given as late as 48h after infection, 20 micrograms polyI,C -LC prevented viremia, and single or multiple dose induces high levels of serum interferon that peaked 24 h after administration of the compound. As late as 48 h postinfection, a high degree of therapeutic synergism was achieved with the combined administration of polyI,C-LC and the antiviral compound ribavirin, using doses that were not effective alone. Keywords Antiviral Immunomodulator Interferon induction Therapeutic and prophylactic efficacy Therapeutic synergism.
- Medicine and Medical Research